

Standing Way
Eaglestone
Milton Keynes
MK6 5LD
01908 660033**Request under Freedom of Information Act 2000**

Thank you for your request for information which we received on 15th December 2023. I am pleased to confirm the following.

Q1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

- Ipilimumab (monotherapy)-0
- Nivolumab (monotherapy)-0
- Nivolumab AND Ipilimumab (combination)-0
- Pembrolizumab-0
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib) -0
- Other active systemic anti-cancer therapy -0

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal cell carcinoma?

- Nivolumab (monotherapy)-0
- Nivolumab + Ipilimumab-0
- Nivolumab + Cabozantinib-0
- Avelumab + Axitinib-0

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Q3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- Nivolumab monotherapy or in combination with Ipilimumab-1
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-2
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-3

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.